By Colin Kellaher Entrada Therapeutics shares slid on Wednesday after the biopharmaceutical company said the Food and Drug Administration wouldn't lift the.
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $16.67, but opened at $15.90. Entrada Therapeutics shares last traded at $15.47, with a volume of 5,380 shares. Analyst Upgrades and Downgrades Separately, HC Wainwright reiterated a “buy” rating and […]
Health-care companies continued mild gains on demand for defensive sectors. Sen. Elizabeth Warren (D., Mass.) and Sen. Mike Braun (R., Ind.) called on the.
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $16.23, for a total transaction of $16,230.00. Following the completion of the sale, the chief executive officer now directly owns 246,279 […]
HC Wainwright reissued their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) in a research report report published on Friday morning, Benzinga reports. The firm currently has a $25.00 price objective on the stock. Entrada Therapeutics Trading Up 3.5 % Shares of NASDAQ TRDA opened at $14.93 on Friday. The stock has […]